I agree. The market doesn't believe the pending final approval for thalidomide will happen. Once it sees the approval which can happen any day, the stock should take off. The company can start sales almost immediately, & that should show in the first qtr. The BASF deal is intriguing, in that the stock appears to have no value built into it for the agro's. Spin off of the agro's could unlock a nice value. I believe the general climate for biotechs will also improve in '98, which should also be a boost. I see a $20 minimum by late '98 early '99. The unknown is the off label usage of thalomid, which lately has gotten great publicity. If that takes off, then this stock could be a Grand Slam.